Condition: Hypertrophic Cardiomyopathy (HCM) · Sponsor: Oregon Health and Science University
This is an investigator-initiated two-center study. The goal of this study is to investigate the feasibility, safety and efficacy outcomes of a seamless transition from mavacamten to aficamten in patients with obstructive hypertrophic cardiomyopathy (oHCM).
This description comes directly from the study's public registry record.
Ahmad Masri · 503-494-7551 · masria@ohsu.edu
Always discuss trial participation with your own doctor first.
| St. Luke's Hospital - Mid America Heart Institute | Kansas City, Missouri, United States | Not Yet Recruiting |
| Oregon Health & Science University | Portland, Oregon, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07600177